MALİGN ROMATOİD ARTRİT 

Tanım: Kayda değer iç organ lezyonlarıyla komplike romatoid artrit formudur. Vasküler lezyonlarla sık komplikasyonlar izlenir. Romatoid faktörler angiitis‘ten sorumludur. 

Gerekçe: Vücudun kendi gama globulinlerine karşı gelişen oto-immün antikorların, romatoid faktörlerin (IgM, IgG and IgA) uzaklaştırılması hedeflenir. 

İşlem: IA, DFPP, CF, Adsorbtif Sitaferez 

İşlenen Volüm: 1 TPH 

Sıklığı: Haftalık 

Replasman Sıvısı: Yok 

Uygulama sayı ve/veya süresi: İşlemlerde plazma kolondan geçirilerek, 20 ml/dak‘yı geçmeyecek; kan ise 50 ml/dak‘yı geçmeyecek Ģekilde reinfüze edilir. 

12 hafta boyunca haftada 1 işlem olacak şekilde bir kür tamamlanır (Adsorbtif sitaferez için haftalık birer işlem olacak şekilde 1 kür 5 işlemden oluşur). 

YARARLANILAN LİTERATÜRLER

*Bosch T. Therapeutic apheresis—state of the art in the year 2005. Ther Apher Dial 2005;9:459–468. 

*Braun-Moscovici Y, Furst DE. Plasmapheresis for rheumatic diseases in the twenty-first century: take it or leave it? Curr Opin Rheumatol 2003;15:197–204. 

*Felson DT, LaValley MP, Baldassare AR, Block JA, Caldwell JR, Cannon GW, Deal C, Evans S, Fleischmann R, Gendreau RM, Harris ER, Matteson EL, Roth SH, Schumacher HR, Weisman MH, Furst DE. The Prosorba column for treatment of refractory rheumatoid arthritis: a randomized, double-blind, sham-controlled trial. Arthritis Rheum 1999;42:2153–2159. 

*Gendreau RM. A randomized double-blind sham-controlled trial of the Prosorba column for treatment of refractory rheumatoid arthritis. Ther Apher 2001;5:79–83. 

*Sasso EH, Merrill C, Furst TE. Immunoglobulin binding properties of the Prosorba immunadsorption column in treatment of rheumatoid arthritis. Ther Apher 2001;5:84–91. 

*Wiesenhutter CW, Irish BL, Bertram JH. Treatment of patients with refractory rheumatoid arthritis with extracorporeal protein A immunoadsorption columns: a pilot trial. J Rheumatol 1994;21:804–812. 

*Genovese MC, Harris ED. Treatment of rheumatoid arthritis. In: Harris FJ, Budd RC, Firestein GS, Genovese MC, Sergent JS, Ruddy S, Sledge CB, editors. Kelley‘s Textbook of Rheumatology, 7th ed. Philadelphia: Elsevier, Saunders, W. B. 2005. pp 1079–1096. 

*Sasso EH, He Y, Merrill C, Furst TE. prosorba treatment of rheumatoid arthritis induces anti-staphylococcal protein a activity earlier in responders than non-responders. Arthritis Rheum 2000;43(Supplement):S290. 

*Haraoui B. Assessment and management of rheumatoid arthritis. J Rheumatol Suppl 2009;82:2–10. 650. Poullin P, Announ N, Mugnier B, Guis S, Roudier J, Lefevre P. Protein A-immunoadsorption (Prosorba column) in the treatment of rheumatoid arthritis. Joint Bone Spine 2005;72:101–103. 

*Roth S. Effects of Prosorba column apheresis in patients with chronic refractory rheumatoid arthritis. J Rheumatol 2004;31:2131–2135. 

*Furst D, Felson D, Thoren G, Gendreau RM; Prosorba Trial Investigators. Immunoadsorption for the treatment of rheumatoid arthritis: final results of a randomized trial. Ther Apher 2000;4:363–373. 

*Goodyear CS, Sugiyama F, Silverman GJ. Temporal and dosedependent relationships between in vivo B cell receptor-targeted proliferation and deletion-induced by a microbial B cell toxin. J Immunol 2006;176:2262–2271. 

*Yu X, Ma J, Tian J, Jiang S, Xu P, Han H, Wang L. A controlled study of double filtration plasmapheresis in the treatment of active rheumatoid arthritis. J Clin Rheumatol 2007;13:193